Priced Oct 29, 2026 · range was $15–$17 · latest SEC filing Nov 9, 2026.
Pinch-zoom for details.
Clinical-stage biotech developing stem-cell therapies made from a patient's own cells (iPSC-derived) for neurodegenerative diseases; its lead candidate is sasineprocel.
Fiscal year
1st half
Fiscal year
1st half
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Operating result | (53.5M) | (59.3M) | −10.9% | (30.9M) | (38.2M) | −23.7% |
| Net result | (48.6M) | (62.1M) | −27.8% | (31.8M) | (36.5M) | −15.1% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (53.5M) | (59.3M) | −10.9% |
| Net result | (48.6M) | (62.1M) | −27.8% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (30.9M) | (38.2M) | −23.7% |
| Net result | (31.8M) | (36.5M) | −15.1% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing's own risk-factor headings, shortened.
The filing's own strategy headings, shortened.
Source: Aspen Neuroscience, Inc.'s Form 424B4, filed with the SEC on Oct 30, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back